Barron'sAlzheimer's Drugs May Be a Big-Pharma Payday. Lilly and Biogen Are Facing Off.Jul 18, 2023Josh Nathan-kazisBy Josh Nathan-kazismore_vert
Alzheimer's Research UK“Another milestone” – successful phase 3 trial of Alzheimer's drug, donanemab, confirmedJul 17, 2023more_vert
HealthlineThere May Be Two FDA-Approved Medication to Slow Alzheimer's DiseaseJul 19, 2023Shawn RadcliffeBy Shawn Radcliffemore_vert
The GuardianExperts urge health regulators to approve ‘turning point’ dementia drugsJul 17, 2023Andrew GregoryBy Andrew Gregorymore_vert
the1a.orgWhat new Alzheimer's drugs can promise patientsJul 19, 2023June LefflerBy June Lefflermore_vert
CNBCEli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the yearJul 17, 2023Annika Kim ConstantinoBy Annika Kim Constantinomore_vert
Financial TimesEli Lilly drug shown to slow Alzheimer's progressionJul 17, 2023Clive CooksonBy Clive Cooksonmore_vert
NPRExperimental Alzheimer's drug donanemab outperforms Leqembi in clinical trial : Shots - Health NewsJul 17, 2023Jon HamiltonBy Jon Hamiltonmore_vert
Science News MagazineNew Alzheimer's drugs are coming. Here's what you need to knowJul 17, 2023Laura SandersBy Laura Sandersmore_vert
The Associated PressSecond Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskJul 17, 2023Lauran NeergaardBy Lauran Neergaardmore_vert
Investors | Eli Lilly and CompanyResults from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and ...Jul 17, 2023more_vert
ScienceAlzheimer's trial shows clear benefits and significant risks of Eli Lilly antibodyJul 17, 2023Jennifer CouzinBy Jennifer Couzinmore_vert
BBCDrug donanemab seen as turning point in dementia fightJul 17, 2023Fergus Walsh & Michelle RobertsBy Fergus Walsh & Michelle Robertsmore_vert
The New York TimesNew Study Finds Alzheimer's Drug Donanemab Can Modestly Slow Memory DeclineJul 17, 2023Pam BelluckBy Pam Belluckmore_vert
ABC NewsNew class of Alzheimer's drugs showing promise in patients in early stage of diseaseJul 17, 2023Alison BranleyBy Alison Branleymore_vert
ReutersLilly drug slows Alzheimer's by 60% for mildly impaired patients in trialJul 17, 2023Deena BeasleyBy Deena Beasleymore_vert
NBC NewsEli Lilly’s Alzheimer’s drug slows memory decline, study findsJul 17, 2023Berkeley Lovelace & Berkeley Lovelace Jr.By Berkeley Lovelace & Berkeley Lovelace Jr.more_vert
CNNSecond Alzheimer’s drug to slow disease’s progression may be approved in the US this yearJul 17, 2023Meg TirrellBy Meg Tirrellmore_vert
Sky NewsDonanemab found to slow Alzheimer's and hailed a 'turning point in fight against disease'Jul 17, 2023Samuel OsborneBy Samuel Osbornemore_vert
The Washington PostEli Lilly's experimental Alzheimer's drug slows disease, data showJul 17, 2023Laurie McGinleyBy Laurie McGinleymore_vert
The ConversationAlzheimer's drug donanemab has been hailed as a 'turning point' for treatment. But what does it mean for people with ...Jul 19, 2023Steve MacfarlaneBy Steve Macfarlanemore_vert
The GuardianWhat impact will Alzheimer’s drug donanemab have?Jul 17, 2023Ian SampleBy Ian Samplemore_vert